Search results for "Thromboxane"

showing 10 items of 64 documents

Decreased bioavailability of nitric oxide in aorta from ovariectomized senescent mice. Role of cyclooxygenase.

2015

This study investigates the effects of aging and/or ovariectomy on vascular reactivity to thromboxane A2 (TXA2) receptor stimulation with U46619, and the modulation by nitric oxide (NO) and cyclooxygenase (COX) in aorta from female senescence-accelerated mice (SAMP8) and from senescence resistant mice (SAMR1). Five-month-old female SAMR1 and SAMP8 were divided into three groups: sham-operated, ovariectomized and ovariectomized plus estradiol. Twenty-eight days after surgery, thoracic aortic rings were mounted for isometric recording of tension and concentration-response curves for U46619 (10(-10)-3 × 10(-7) M) were performed in the absence and in the presence of the NO synthase inhibitor N(…

0301 basic medicineAgingReceptors ThromboxaneAorta Thoracic030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compoundThromboxane A2Mice0302 clinical medicineEndocrinologySuperoxidesThoracic aortaVasoconstrictor AgentsbiologyEstradiolSuperoxideEstrogen Replacement TherapyAge FactorsOvariectomized ratFemaleMenopauseSignal Transductionmedicine.medical_specialtymedicine.drug_classOvariectomyDown-RegulationNitric OxideNitric oxide03 medical and health sciencesThromboxane A2medicine.arteryInternal medicineGeneticsmedicineAnimalsCyclooxygenase InhibitorsMolecular BiologyAortaDose-Response Relationship Drugbusiness.industryCell BiologyEnzyme ActivationOxidative Stress030104 developmental biologyEndocrinologychemistryEstrogenProstaglandin-Endoperoxide SynthasesVasoconstrictionbiology.proteinCyclooxygenaseNitric Oxide SynthasebusinessExperimental gerontology
researchProduct

Stenosis coexists with compromised α1-adrenergic contractions in the ascending aorta of a mouse model of Williams-Beuren syndrome

2020

Williams-Beuren syndrome (WBS) is a rare disorder caused by a heterozygous deletion of 26-28 contiguous genes that affects the brain and cardiovascular system. Here, we investigated whether WBS affects aortic structure and function in the complete deletion (CD) mouse model harbouring the most common deletion found in WBS patients. Thoracic aortas from 3-4 months-old male CD mice and wild-type littermates were mounted in wire myographs or were processed for histomorphometrical analysis. Nitric oxide synthase (NOS) isoforms and oxidative stress levels were assessed. Ascending aortas from young adult CD mice showed moderate (50%) luminal stenosis, whereas endothelial function and oxidative str…

0301 basic medicineMaleWilliams SyndromeThromboxaneAdrenergiclcsh:MedicineAorta ThoracicNitric Oxide Synthase Type I030204 cardiovascular system & hematologymedicine.disease_causeAortic diseasesPhenylephrine0302 clinical medicineEthidiumMalalties hereditàrieslcsh:ScienceStenosisMultidisciplinarybiologyAnimal models in researchNitric oxide synthaseAortic Stenosis SupravalvularCardiovascular diseasesmedicine.drugGenetic diseasesmedicine.medical_specialtyNitric OxideArticle03 medical and health sciencesInternal medicinemedicine.arteryReceptors Adrenergic alpha-1Ascending aortamedicineAnimalsEstenosiPhenylephrinebusiness.industryMalalties cardiovascularslcsh:Rmedicine.diseaseValvular diseaseMice Mutant StrainsBlockadeElastinStenosisDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologybiology.proteinlcsh:QEndothelium VascularModels animals en la investigacióbusinessOxidative stressScientific Reports
researchProduct

Extracellular histones disarrange vasoactive mediators reléase through COX-NOS interaction in human endothelial cells

2017

Abstract Extracellular histones are mediators of inflammation, tissue injury and organ dysfunction. Interactions between circulating histones and vascular endothelial cells are key events in histone‐mediated pathologies. Our aim was to investigate the implication of extracellular histones in the production of the major vasoactive compounds released by human endothelial cells (HUVECs), prostanoids and nitric oxide (NO). HUVEC exposed to increasing concentrations of histones (0.001 to 100 μg/ml) for 4 hrs induced prostacyclin (PGI2) production in a dose‐dependent manner and decreased thromboxane A2 (TXA2) release at 100 μg/ml. Extracellular histones raised cyclooxygenase‐2 (COX‐2) and prostac…

0301 basic medicineProstacyclinHistoneschemistry.chemical_compoundThromboxane A2Cytochrome P-450 Enzyme SystemSuperoxidesEnosvascular mediatorsGenètica humanabiologySuperoxideendothelial cellsIntramolecular OxidoreductasesEndothelial stem cellMolecular MedicineOriginal ArticleThromboxane-A SynthaseSignal Transductionmedicine.drugmedicine.medical_specialtyNitric Oxide Synthase Type IIIPrimary Cell CultureNitric OxideProstacyclin synthaseNitric oxideCyclic N-OxidesThromboxane A203 medical and health sciencesInternal medicineHuman Umbilical Vein Endothelial CellsmedicineExtracellularHumansRNA MessengerprostanoidsDose-Response Relationship DrugOriginal ArticlesCell Biologybiology.organism_classificationEpoprostenolÒxid nítric030104 developmental biologyEndocrinologyGene Expression RegulationchemistryCelecoxibCyclooxygenase 2Cyclooxygenase 1biology.proteinSpin LabelsProteïnesextracellular histones
researchProduct

COVID-19 Sepsis and Microcirculation Dysfunction

2020

The spreading of Coronavirus (SARS-CoV-2) pandemic, known as COVID-19, has caused a great number of fatalities all around the World. Up to date (2020 May 6) in Italy we had more than 28,000 deaths, while there were more than 205.000 infected. The majority of patients affected by COVID-19 complained only slight symptoms: fatigue, myalgia or cough, but more than 15% of Chinese patients progressed into severe complications, with acute respiratory distress syndrome (ARDS), needing intensive treatment. We tried to summarize data reported in the last months from several Countries, highlighting that COVID-19 was characterized by cytokine storm (CS) and endothelial dysfunction in severely ill patie…

0301 basic medicinemyalgiamedicine.medical_specialtyARDSPhysiologyMini ReviewmicrocirculationDiseaseangiotensin II030204 cardiovascular system & hematologylcsh:PhysiologyMicrocirculationSepsis03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineEndothelial dysfunctionIntensive care medicinethromboxane (TxB2)lcsh:QP1-981business.industryangiotensin II; COVID-19; endothelial cells; microcirculation; thromboxane (TxB2)COVID-19medicine.diseaseAngiotensin IIendothelial cells030104 developmental biologymedicine.symptomCytokine stormbusinessFrontiers in Physiology
researchProduct

Endogenous peroxynitrite modulates PGHS-1–dependent thromboxane A2 formation and aggregation in human platelets

2008

Aggregation of activated platelets is considerably mediated by the autocrine action of thromboxane A2 (TxA2) which is formed in a prostaglandin endoperoxide H2 synthase-1 (PGHS-1 or COX-1)-dependent manner. The activity of PGHS-1 can be stimulated by peroxides, an effect termed "peroxide tone", that renders PGHS-1 the key regulatory enzyme in the formation of TxA2. Activated platelets release nitric oxide (*NO) and superoxide (O*2) but their interactions with the prostanoid pathway have been controversially discussed in platelet physiology and pathophysiology. The current study demonstrates that endogenously formed peroxynitrite at nanomolar concentrations, originating from the interaction …

1303 BiochemistryPlatelet AggregationSuperoxideProstanoid610 Medicine & healthBiochemistryNitric oxideCell biologychemistry.chemical_compoundPeroxynitrous acidThromboxane A2Thromboxane A22737 Physiology (medical)BiochemistrychemistryPhysiology (medical)Peroxynitrous Acid10209 Clinic for CardiologyCyclooxygenase 1Humanslipids (amino acids peptides and proteins)PlateletPlatelet activationPeroxynitrite
researchProduct

ABNORMALLY HIGH THROMBOXANE BIOSYNTHESIS IN HOMOZYGOUS HOMOCYSTINURIA. EVIDENCE FOR PLATELET INVOLVEMENT AND PROBUCOL-SENSITIVE MECHANISM.

1993

Homocystinuria due to homozygous cystathionine beta-synthase deficiency is an inborn error of metabolism characterized by a high incidence of thrombosis and premature atherosclerosis. We evaluated TXA2 biosynthesis in vivo and several in vitro tests of platelet function in 11 homocystinuric patients and 12 healthy controls. In vitro, patients' platelet aggregation was within control values as were TXB2 formation, fibrinogen binding, and ATP secretion in response to thrombin. In contrast, the urinary excretion of 11-dehydro-TXB2, a major enzymatic derivative of TXA2, was > 2 SD of controls in all patients (1,724 +/- 828 pg/mg creatinine, mean +/- SD, in patients vs. 345 +/- 136 in controls, …

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentPlatelet AggregationThromboxaneProbucolHomocystinuriaInternal medicinemedicineHumansPlateletPlatelet activationChildBlood CoagulationbiologyAspirinChemistryFibrinolysisHomozygoteFibrinogen bindingThromboxanesGeneral Medicinemedicine.diseaseCystathionine beta synthaseEndocrinologyProbucolbiology.proteinlipids (amino acids peptides and proteins)FemaleHomocystinuriaCyclooxygenasemedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Increased thromboxane biosynthesis in type IIa hypercholesterolemia.

1992

BACKGROUND Increased platelet thromboxane (TX)A2 production has been described in type IIa hypercholesterolemia. To verify the relevance of these capacity-related measurements to the actual rate of TXA2 biosynthesis in vivo, we studied the urinary excretion of its major enzymatic metabolites in 46 patients with type IIa hypercholesterolemia and 20 age-matched controls. METHODS AND RESULTS Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were measured by previously validated radioimmunoassays. The excretion rate of 11-dehydro-TXB2 was significantly (p less than 0.001) higher in patients (68.7 +/- 35.1 ng/hr, mean +/- SD) than in controls (22.4 +/- 9.4 ng/hr), with metabolite excretion greater tha…

AdultBlood PlateletsMalemedicine.medical_specialtySimvastatinThromboxaneMetaboliteHypercholesterolemiaExcretionchemistry.chemical_compoundThromboxane A2Physiology (medical)Internal medicinemedicineHumansPlateletPlatelet activationLovastatinAgedbiologyAspirinDose-Response Relationship Drugbusiness.industryCholesterolAnticholesteremic AgentsMiddle AgedEndocrinologychemistrySimvastatinbiology.proteinlipids (amino acids peptides and proteins)FemaleCyclooxygenaseCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1995

Abstract Thromboxane A 2 (TXA 2 ) biosynthesis is enhanced in the majority of patients with type IIa hypercholesterolemia. Because simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) was previously shown to reduce platelet aggregation and TXB 2 production ex vivo, we investigated TXA 2 biosynthesis and platelet function in 24 patients with type IIa hypercholesterolemia randomized to receive in a double-blind fashion simvastatin (20 mg/d) or placebo for 3 months. The urinary excretion of 11-dehydro-TXB 2 , largely a reflection of platelet TXA 2 production in vivo, was measured by a previously validated radioimmunoassay technique. Blood lipid levels and urinary 11-dehyd…

AdultMaleBlood lipoproteinSimvastatinmedicine.medical_specialtyPlatelet AggregationApolipoprotein BThromboxaneHypercholesterolemiaBlood lipidsThromboxane A2chemistry.chemical_compoundThromboxane A2Double-Blind MethodInternal medicinemedicineHumansPlateletLovastatinAgedbiologyChemistryCholesterolAnticholesteremic AgentsMiddle AgedLipid MetabolismCholesterolEndocrinologySimvastatinbiology.proteinFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinePlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers

2011

AdultMalePlatelet aggregationPlatelet AggregationFlowerslaw.inventionYoung AdultRandomized controlled trialFibrinolytic AgentslawHealthy volunteersMedicineHumansAnalysis of VarianceCrataegusCross-Over StudiesbiologyTraditional medicineAspirinbusiness.industryPlant ExtractsHematologybiology.organism_classificationCrossover studyCrataegus laevigataPlant LeavesThromboxane B2SpainFemaleAnalysis of variancebusinessPlatelet Aggregation Inhibitors
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct